Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Payables (2016 - 2025)

Historic Payables for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $7.6 million.

  • Collegium Pharmaceutical's Payables rose 14338.0% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year increase of 14338.0%. This contributed to the annual value of $3.9 million for FY2024, which is 5474.0% down from last year.
  • Latest data reveals that Collegium Pharmaceutical reported Payables of $7.6 million as of Q3 2025, which was up 14338.0% from $10.9 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Payables ranged from a high of $17.9 million in Q1 2025 and a low of $2.4 million during Q2 2024
  • Moreover, its 5-year median value for Payables was $6.0 million (2024), whereas its average is $6.3 million.
  • As far as peak fluctuations go, Collegium Pharmaceutical's Payables tumbled by 6348.27% in 2023, and later surged by 35149.25% in 2025.
  • Quarter analysis of 5 years shows Collegium Pharmaceutical's Payables stood at $4.2 million in 2021, then dropped by 16.59% to $3.5 million in 2022, then soared by 148.77% to $8.7 million in 2023, then tumbled by 54.74% to $3.9 million in 2024, then skyrocketed by 94.38% to $7.6 million in 2025.
  • Its Payables stands at $7.6 million for Q3 2025, versus $10.9 million for Q2 2025 and $17.9 million for Q1 2025.